Venous thromboembolic disease

Lawrence D. Wagman, Melissa F. Baird, Charles L. Bennett, Paula L. Bockenstedt, Spero R. Cataland, John Fanikos, Patrick F. Fogarty, Samuel Z. Goldhaber, Tejpal S. Grover, William Haire, Hani Hassoun, Suzanne Hutchinson, Mohammad Jahanzeb, Jason Lee, Michael L. Linenberger, Michael M. Millenson, Thomas L. Ortel, Riad Salem, Judy L. Smith, Michael B. StreiffSuresh Vedantham

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Recognizing the increased risk for VTE in cancer patients is the first step in preventing its occurrence and promptly identifying it in these patients. The panel recommends VTE thromboprophylaxis for all hospitalized patients with cancer who have no contraindications to this therapy, and also emphasizes that an increased level of clinical suspicion of VTE should be maintained for cancer patients. After hospital discharge, the panel recommends that patients at high risk for VTE (e.g., patients who have undergone surgery for cancer) continue to receive VTE prophylaxis for up to 4 weeks postoperation. Careful evaluation and follow-up of cancer patients in whom VTE is suspected, and prompt treatment and follow-up for those diagnosed with VTE is recommended after the cancer status of the patient is assessed and the risks and benefits of treatment are considered.

Original languageEnglish (US)
Pages (from-to)716-753
Number of pages38
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume6
Issue number8
StatePublished - Sep 1 2008

Fingerprint

Neoplasms
Therapeutics

Keywords

  • Anti-coagulation
  • Cancer
  • Deep venous thrombosis
  • Heparin
  • NCCN Clinical Practice Guidelines
  • Prophylaxis
  • Pulmonary embolism
  • Treatment
  • Venous thromboembolism

ASJC Scopus subject areas

  • Oncology

Cite this

Wagman, L. D., Baird, M. F., Bennett, C. L., Bockenstedt, P. L., Cataland, S. R., Fanikos, J., ... Vedantham, S. (2008). Venous thromboembolic disease. JNCCN Journal of the National Comprehensive Cancer Network, 6(8), 716-753.
Wagman, Lawrence D. ; Baird, Melissa F. ; Bennett, Charles L. ; Bockenstedt, Paula L. ; Cataland, Spero R. ; Fanikos, John ; Fogarty, Patrick F. ; Goldhaber, Samuel Z. ; Grover, Tejpal S. ; Haire, William ; Hassoun, Hani ; Hutchinson, Suzanne ; Jahanzeb, Mohammad ; Lee, Jason ; Linenberger, Michael L. ; Millenson, Michael M. ; Ortel, Thomas L. ; Salem, Riad ; Smith, Judy L. ; Streiff, Michael B. ; Vedantham, Suresh. / Venous thromboembolic disease. In: JNCCN Journal of the National Comprehensive Cancer Network. 2008 ; Vol. 6, No. 8. pp. 716-753.
@article{c16cc099cd8b44cfbf3ea3c3c15fa2fd,
title = "Venous thromboembolic disease",
abstract = "Recognizing the increased risk for VTE in cancer patients is the first step in preventing its occurrence and promptly identifying it in these patients. The panel recommends VTE thromboprophylaxis for all hospitalized patients with cancer who have no contraindications to this therapy, and also emphasizes that an increased level of clinical suspicion of VTE should be maintained for cancer patients. After hospital discharge, the panel recommends that patients at high risk for VTE (e.g., patients who have undergone surgery for cancer) continue to receive VTE prophylaxis for up to 4 weeks postoperation. Careful evaluation and follow-up of cancer patients in whom VTE is suspected, and prompt treatment and follow-up for those diagnosed with VTE is recommended after the cancer status of the patient is assessed and the risks and benefits of treatment are considered.",
keywords = "Anti-coagulation, Cancer, Deep venous thrombosis, Heparin, NCCN Clinical Practice Guidelines, Prophylaxis, Pulmonary embolism, Treatment, Venous thromboembolism",
author = "Wagman, {Lawrence D.} and Baird, {Melissa F.} and Bennett, {Charles L.} and Bockenstedt, {Paula L.} and Cataland, {Spero R.} and John Fanikos and Fogarty, {Patrick F.} and Goldhaber, {Samuel Z.} and Grover, {Tejpal S.} and William Haire and Hani Hassoun and Suzanne Hutchinson and Mohammad Jahanzeb and Jason Lee and Linenberger, {Michael L.} and Millenson, {Michael M.} and Ortel, {Thomas L.} and Riad Salem and Smith, {Judy L.} and Streiff, {Michael B.} and Suresh Vedantham",
year = "2008",
month = "9",
day = "1",
language = "English (US)",
volume = "6",
pages = "716--753",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "8",

}

Wagman, LD, Baird, MF, Bennett, CL, Bockenstedt, PL, Cataland, SR, Fanikos, J, Fogarty, PF, Goldhaber, SZ, Grover, TS, Haire, W, Hassoun, H, Hutchinson, S, Jahanzeb, M, Lee, J, Linenberger, ML, Millenson, MM, Ortel, TL, Salem, R, Smith, JL, Streiff, MB & Vedantham, S 2008, 'Venous thromboembolic disease', JNCCN Journal of the National Comprehensive Cancer Network, vol. 6, no. 8, pp. 716-753.

Venous thromboembolic disease. / Wagman, Lawrence D.; Baird, Melissa F.; Bennett, Charles L.; Bockenstedt, Paula L.; Cataland, Spero R.; Fanikos, John; Fogarty, Patrick F.; Goldhaber, Samuel Z.; Grover, Tejpal S.; Haire, William; Hassoun, Hani; Hutchinson, Suzanne; Jahanzeb, Mohammad; Lee, Jason; Linenberger, Michael L.; Millenson, Michael M.; Ortel, Thomas L.; Salem, Riad; Smith, Judy L.; Streiff, Michael B.; Vedantham, Suresh.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 6, No. 8, 01.09.2008, p. 716-753.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Venous thromboembolic disease

AU - Wagman, Lawrence D.

AU - Baird, Melissa F.

AU - Bennett, Charles L.

AU - Bockenstedt, Paula L.

AU - Cataland, Spero R.

AU - Fanikos, John

AU - Fogarty, Patrick F.

AU - Goldhaber, Samuel Z.

AU - Grover, Tejpal S.

AU - Haire, William

AU - Hassoun, Hani

AU - Hutchinson, Suzanne

AU - Jahanzeb, Mohammad

AU - Lee, Jason

AU - Linenberger, Michael L.

AU - Millenson, Michael M.

AU - Ortel, Thomas L.

AU - Salem, Riad

AU - Smith, Judy L.

AU - Streiff, Michael B.

AU - Vedantham, Suresh

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Recognizing the increased risk for VTE in cancer patients is the first step in preventing its occurrence and promptly identifying it in these patients. The panel recommends VTE thromboprophylaxis for all hospitalized patients with cancer who have no contraindications to this therapy, and also emphasizes that an increased level of clinical suspicion of VTE should be maintained for cancer patients. After hospital discharge, the panel recommends that patients at high risk for VTE (e.g., patients who have undergone surgery for cancer) continue to receive VTE prophylaxis for up to 4 weeks postoperation. Careful evaluation and follow-up of cancer patients in whom VTE is suspected, and prompt treatment and follow-up for those diagnosed with VTE is recommended after the cancer status of the patient is assessed and the risks and benefits of treatment are considered.

AB - Recognizing the increased risk for VTE in cancer patients is the first step in preventing its occurrence and promptly identifying it in these patients. The panel recommends VTE thromboprophylaxis for all hospitalized patients with cancer who have no contraindications to this therapy, and also emphasizes that an increased level of clinical suspicion of VTE should be maintained for cancer patients. After hospital discharge, the panel recommends that patients at high risk for VTE (e.g., patients who have undergone surgery for cancer) continue to receive VTE prophylaxis for up to 4 weeks postoperation. Careful evaluation and follow-up of cancer patients in whom VTE is suspected, and prompt treatment and follow-up for those diagnosed with VTE is recommended after the cancer status of the patient is assessed and the risks and benefits of treatment are considered.

KW - Anti-coagulation

KW - Cancer

KW - Deep venous thrombosis

KW - Heparin

KW - NCCN Clinical Practice Guidelines

KW - Prophylaxis

KW - Pulmonary embolism

KW - Treatment

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=52949107527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52949107527&partnerID=8YFLogxK

M3 - Article

C2 - 18926086

AN - SCOPUS:52949107527

VL - 6

SP - 716

EP - 753

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 8

ER -

Wagman LD, Baird MF, Bennett CL, Bockenstedt PL, Cataland SR, Fanikos J et al. Venous thromboembolic disease. JNCCN Journal of the National Comprehensive Cancer Network. 2008 Sep 1;6(8):716-753.